Reply to Dorgham et al., "Considering Personalized Interferon Beta Therapy for COVID-19".
作者信息
Davoudi-Monfared Effat, Khalili Hossein
机构信息
Department of Pharmacotherapy, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Department of Pharmacotherapy, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
出版信息
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.00083-21.
Abstract
摘要
相似文献
1
Reply to Dorgham et al., "Considering Personalized Interferon Beta Therapy for COVID-19".对多尔加姆等人《考虑针对新冠肺炎的个性化干扰素β治疗》一文的回复
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.00083-21.
2
Considering Personalized Interferon Beta Therapy for COVID-19.考虑针对COVID-19的个性化干扰素β疗法。
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.00065-21.
3
Nebulised interferon beta-1a for patients with COVID-19.雾化吸入干扰素β-1a用于治疗新型冠状病毒肺炎患者。
Lancet Respir Med. 2021 Feb;9(2):122-123. doi: 10.1016/S2213-2600(20)30523-3. Epub 2020 Nov 12.
4
Interferon beta-1a for COVID-19: critical importance of the administration route.用于治疗新型冠状病毒肺炎的β-1a干扰素：给药途径的关键重要性
Crit Care. 2020 Jun 12;24(1):335. doi: 10.1186/s13054-020-03048-5.
5
The double edged interferon riddle in COVID-19 pathogenesis.新冠病毒发病机制中的双刃剑——干扰素之谜
Crit Care. 2020 Nov 1;24(1):631. doi: 10.1186/s13054-020-03337-z.
6
Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection.干扰素-β-1a 对病毒感染后给药时体外严重急性呼吸综合征冠状病毒 2 的抑制作用。
J Infect Dis. 2020 Aug 4;222(5):722-725. doi: 10.1093/infdis/jiaa350.
7
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.一项干扰素 β-1a 治疗重症 COVID-19 的疗效和安全性的随机临床试验。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01061-20.
8
Subcutaneous interferon beta-1a in COVID-19: raking the ashes of an intervention trial.皮下注射干扰素β-1a治疗新型冠状病毒肺炎：一项干预试验的复盘
Lancet Respir Med. 2021 Dec;9(12):1344-1345. doi: 10.1016/S2213-2600(21)00412-4. Epub 2021 Oct 18.
9
Lack of efficacy of Interferon β-1a in COVID-19 patients with mild to moderate pneumonia.β-1a干扰素对轻至中度肺炎COVID-19患者无效。
Eur J Intern Med. 2023 Apr;110:104-106. doi: 10.1016/j.ejim.2022.11.033. Epub 2022 Dec 2.
10
Reply to Blot and to Inoue .回复布洛特和井上文。
Am J Respir Crit Care Med. 2021 Jan 1;203(1):141-142. doi: 10.1164/rccm.202008-3169LE.
本文引用的文献
1
Considering Personalized Interferon Beta Therapy for COVID-19.考虑针对COVID-19的个性化干扰素β疗法。
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.00065-21.
2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling.严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的膜（M）蛋白通过靶向 RIG-I/MDA-5 信号通路抑制 I 型和 III 型干扰素的产生。
Signal Transduct Target Ther. 2020 Dec 28;5(1):299. doi: 10.1038/s41392-020-00438-7.
3
The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19.I 型干扰素在 COVID-19 发病机制和治疗中的作用。
Front Immunol. 2020 Sep 30;11:595739. doi: 10.3389/fimmu.2020.595739. eCollection 2020.
4
Activation and evasion of type I interferon responses by SARS-CoV-2.SARS-CoV-2 激活和逃避 I 型干扰素应答。
Nat Commun. 2020 Jul 30;11(1):3810. doi: 10.1038/s41467-020-17665-9.
5
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.严重 COVID-19 患者的 I 型干扰素活性和炎症反应受损。
Science. 2020 Aug 7;369(6504):718-724. doi: 10.1126/science.abc6027. Epub 2020 Jul 13.
6
A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.一项干扰素 β-1a 治疗重症 COVID-19 的疗效和安全性的随机临床试验。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01061-20.
7
The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway.SARS-CoV-2 的 ORF6、ORF8 和核衣壳蛋白抑制 I 型干扰素信号通路。
Virus Res. 2020 Sep;286:198074. doi: 10.1016/j.virusres.2020.198074. Epub 2020 Jun 23.
8
Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.I 型和 III 型干扰素 - 诱导、信号转导、逃逸及其在抗击 COVID-19 中的应用。
Cell Host Microbe. 2020 Jun 10;27(6):870-878. doi: 10.1016/j.chom.2020.05.008. Epub 2020 May 27.
9
COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons.COVID-19：干扰素的发病机制、细胞因子风暴和治疗潜力。
Cytokine Growth Factor Rev. 2020 Jun;53:66-70. doi: 10.1016/j.cytogfr.2020.05.002. Epub 2020 May 7.
10
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.我们应该在 COVID-19 中刺激还是抑制免疫反应？细胞因子和抗细胞因子干预。
Autoimmun Rev. 2020 Jul;19(7):102567. doi: 10.1016/j.autrev.2020.102567. Epub 2020 May 4.
Zotero 插件